Consequently, tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) have become the standard treatment for patients with metastatic EGFR‐ or ALK‐mutated lung adenocarcinoma, and these tests are performed in routine practice.5 This evidence concerns the gene ALK and lung adenocarcinoma.